May 20th, 2020

Presentation of “SPI2” Phase III Results at the EAN Virtual Congress 2020
Read more

March 10th, 2020

MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis
Read more

December 12th, 2019

MedDay Reports Last Patient Study Visit in Second Phase 3 Clinical Trial with MD1003®, an Important Milestone Towards Completion of the SPI2 Study in Progressive Multiple Sclerosis
Read more